Foamix stock bubbles higher on latest acne PhIII; Concentric Analgesic gets an FDA 'breakthrough'
→ Shares of Foamix Therapeutics $FOMX soared Tuesday night on news that their third Phase III study of a new acne med succeeded in delivering significant benefits. The numbers may not be overwhelming, with investigators noting that a “mean reduction in inflammatory lesion count at Week 12 relative to baseline was -16.93 for the FMX101 treatment group and -13.40 for the vehicle treatment group (p<0.0001).” But investors loved it. Shares rocketed up more than 50% in after-market trading and were still up 23% in early morning trading Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.